96 related articles for article (PubMed ID: 26902334)
21. Non-Coding RNAs in Castration-Resistant Prostate Cancer: Regulation of Androgen Receptor Signaling and Cancer Metabolism.
Shih JW; Wang LY; Hung CL; Kung HJ; Hsieh CL
Int J Mol Sci; 2015 Dec; 16(12):28943-78. PubMed ID: 26690121
[TBL] [Abstract][Full Text] [Related]
22. LncRNA HOTAIR Enhances the Androgen-Receptor-Mediated Transcriptional Program and Drives Castration-Resistant Prostate Cancer.
Zhang A; Zhao JC; Kim J; Fong KW; Yang YA; Chakravarti D; Mo YY; Yu J
Cell Rep; 2015 Oct; 13(1):209-221. PubMed ID: 26411689
[TBL] [Abstract][Full Text] [Related]
23. [The concept and mechanisms of castration-resistant prostate cancer].
Naito S; Shiota M
Nihon Rinsho; 2014 Dec; 72(12):2090-4. PubMed ID: 25518339
[TBL] [Abstract][Full Text] [Related]
24. Strategies for targeting the androgen receptor axis in prostate cancer.
Carver BS
Drug Discov Today; 2014 Sep; 19(9):1493-7. PubMed ID: 25107669
[TBL] [Abstract][Full Text] [Related]
25. Differentially methylated genes and androgen receptor re-expression in small cell prostate carcinomas.
Kleb B; Estécio MR; Zhang J; Tzelepi V; Chung W; Jelinek J; Navone NM; Tahir S; Marquez VE; Issa JP; Maity S; Aparicio A
Epigenetics; 2016 Mar; 11(3):184-93. PubMed ID: 26890396
[TBL] [Abstract][Full Text] [Related]
26. Treatment Sequencing in Metastatic Castration-Resistant Prostate Cancer: A Clinical Commentary.
Stein CA
Clin Genitourin Cancer; 2015 Oct; 13(5):407-9. PubMed ID: 26119230
[No Abstract] [Full Text] [Related]
27. [Androgen receptor variants in prostate cancer].
Schreyer E; Barthélémy P; Cottard F; Ould Madi-Berthélémy P; Schaff-Wendling F; Kurtz JE; Céraline J
Med Sci (Paris); 2017; 33(8-9):758-764. PubMed ID: 28945566
[TBL] [Abstract][Full Text] [Related]
28. Androgen receptor co-regulatory networks in castration-resistant prostate cancer.
Sung YY; Cheung E
Endocr Relat Cancer; 2014 Feb; 21(1):R1-R11. PubMed ID: 24152433
[TBL] [Abstract][Full Text] [Related]
29. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
30. TCF7 is suppressed by the androgen receptor via microRNA-1-mediated downregulation and is involved in the development of resistance to androgen deprivation in prostate cancer.
Siu MK; Chen WY; Tsai HY; Chen HY; Yin JJ; Chen CL; Tsai YC; Liu YN
Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):172-178. PubMed ID: 28220803
[TBL] [Abstract][Full Text] [Related]
31. The role of TXNDC5 in castration-resistant prostate cancer-involvement of androgen receptor signaling pathway.
Wang L; Song G; Chang X; Tan W; Pan J; Zhu X; Liu Z; Qi M; Yu J; Han B
Oncogene; 2015 Sep; 34(36):4735-45. PubMed ID: 25500540
[TBL] [Abstract][Full Text] [Related]
32. Branched Chain RNA In Situ Hybridization for Androgen Receptor Splice Variant AR-V7 as a Prognostic Biomarker for Metastatic Castration-Sensitive Prostate Cancer.
Saylor PJ; Lee RJ; Arora KS; Deshpande V; Hu R; Olivier K; Meneely E; Rivera MN; Ting DT; Wu CL; Miyamoto DT
Clin Cancer Res; 2017 Jan; 23(2):363-369. PubMed ID: 27440270
[TBL] [Abstract][Full Text] [Related]
33. ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer.
Gao S; Ye H; Gerrin S; Wang H; Sharma A; Chen S; Patnaik A; Sowalsky AG; Voznesensky O; Han W; Yu Z; Mostaghel EA; Nelson PS; Taplin ME; Balk SP; Cai C
Clin Cancer Res; 2016 Jul; 22(14):3672-82. PubMed ID: 26936914
[TBL] [Abstract][Full Text] [Related]
34. Androgen receptor splice variant 7 in castration-resistant prostate cancer: Clinical considerations.
Bryce AH; Antonarakis ES
Int J Urol; 2016 Aug; 23(8):646-53. PubMed ID: 27255944
[TBL] [Abstract][Full Text] [Related]
35. Cathepsin K expression in castration-resistant prostate carcinoma: a therapeutical target for patients at risk for bone metastases.
Munari E; Cima L; Massari F; Bertoldo F; Porcaro AB; Caliò A; Riva G; Ciocchetta E; Ciccarese C; Modena A; Iacovelli R; Sava T; Eccher A; Ghimenton C; Tortora G; Artibani W; Novella G; Bogina G; Zamboni G; Sanguedolce F; D'Amuri A; Martignoni G; Brunelli M
Int J Biol Markers; 2017 May; 32(2):e243-e247. PubMed ID: 28085175
[TBL] [Abstract][Full Text] [Related]
36. Do the expressions of epithelial-mesenchymal transition proteins, periostin, integrin-α4 and fibronectin correlate with clinico-pathological features and prognosis of metastatic castration-resistant prostate cancer?
Konac E; Kiliccioglu I; Sogutdelen E; Dikmen AU; Albayrak G; Bilen CY
Exp Biol Med (Maywood); 2017 Dec; 242(18):1795-1801. PubMed ID: 28836852
[TBL] [Abstract][Full Text] [Related]
37. TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer.
Groner AC; Cato L; de Tribolet-Hardy J; Bernasocchi T; Janouskova H; Melchers D; Houtman R; Cato ACB; Tschopp P; Gu L; Corsinotti A; Zhong Q; Fankhauser C; Fritz C; Poyet C; Wagner U; Guo T; Aebersold R; Garraway LA; Wild PJ; Theurillat JP; Brown M
Cancer Cell; 2016 Jun; 29(6):846-858. PubMed ID: 27238081
[TBL] [Abstract][Full Text] [Related]
38. Secretory leukocyte protease inhibitor is a survival and proliferation factor for castration-resistant prostate cancer.
Zheng D; Gui B; Gray KP; Tinay I; Rafiei S; Huang Q; Sweeney CJ; Kibel AS; Jia L
Oncogene; 2016 Sep; 35(36):4807-15. PubMed ID: 26876202
[TBL] [Abstract][Full Text] [Related]
39. High levels of the AR-V7 Splice Variant and Co-Amplification of the Golgi Protein Coding YIPF6 in AR Amplified Prostate Cancer Bone Metastases.
Djusberg E; Jernberg E; Thysell E; Golovleva I; Lundberg P; Crnalic S; Widmark A; Bergh A; Brattsand M; Wikström P
Prostate; 2017 May; 77(6):625-638. PubMed ID: 28144969
[TBL] [Abstract][Full Text] [Related]
40. Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer.
Guo C; Yeh S; Niu Y; Li G; Zheng J; Li L; Chang C
Cancer Lett; 2017 Jul; 397():133-143. PubMed ID: 28323036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]